PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice

• Published in: Haematologica (Roma) 2013-03, Vol.98 (3), p.424-427
• Main Authors: Omidvar, Nader, Maunakea, Mei Lin, Jones, Letetia, Sevcikova, Sabina, Yin, Bin, Himmel, Karen L, Tennant, Thelma R, Le Beau, Michelle M, Largaespada, David A, Kogan, Scott C
• Format: Article
• Language: English
• Subjects: Animals; Bone Marrow - pathology; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - metabolism; Disease Models, Animal; Gene Expression; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - pathology; Liver - pathology; Lymph Nodes - pathology; Mice; Mice, Transgenic; Oncogene Proteins, Fusion - genetics; Oncogene Proteins, Fusion - metabolism; Protein Binding; SOXC Transcription Factors - genetics; SOXC Transcription Factors - metabolism; Spleen - pathology
• ISSN: 0390-6078; 1592-8721
• DOI: 10.3324/haematol.2011.057067

Acute promyelocytic leukemia is characterized by a chromosomal translocation involving the retinoic acid receptor alpha gene. To identify co-operating pathways to leukemogenesis, we crossed MRP8-PML/RARA transgenic mice with BXH-2 mice which harbor an endogenous murine leukemia virus that causes acute myeloid leukemia. Approximately half of the leukemias that arose in this cross showed features of acute promyelocytic leukemia. We identified 22 proviral insertion sites in acute promyelocytic-like leukemias and focused our analysis on insertion at Sox4, a HMG box transcription factor. Using a transplant model, co-operation between PML-RARα and Sox4 was confirmed with increased penetrance and reduced latency of disease. Interestingly, karyotypic analysis revealed cytogenetic changes suggesting that the factors combined to initiate but not complete leukemic transformation. The cooperation between these transcription factors is consistent with the paradigm of multiple routes to the disease and reinforces the concept that transcription factor networks are important therapeutic targets in myeloid leukemias.